NCT03426969View on ClinicalTrials.gov

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

September 21, 2020

Study Completion Date

September 21, 2020

Conditions
Primary MyelofibrosisSecondary Myelofibrosis
Interventions
DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Fludarabine Phosphate

Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo HCT

DRUG

Melphalan

Given IV

DRUG

Mycophenolate Mofetil

Given PO

DRUG

Tacrolimus

IV or PO

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03426969 - Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | Biotech Hunter | Biotech Hunter